- Clinical Expertise
- Gastro-Intestinal Cancers
- Pancreatic Cancer
- Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
- Appointments
- Assistant Professor of Medicine, Columbia University Medical Center
- Education
- B.A., 1993, Columbia College, Columbia University, New York, NY
- M.D., 1999, Columbia College of Physicians and Surgeons, New York, NY
- M.S., 2005, University of Chicago, Chicago, IL
- Internship & Residency
- Internal Medicine, 2002, Brigham and Women's Hospital, Boston, MA
- Fellowship
- Hematology/Oncology, 2005, University of Chicago Medical Center, Chicago, IL
Michael J. Hall, M.D.
NEW PATIENTS TEL (212) 305-5098
ADMINISTRATIVE OFFICE TEL (212) 305-0592
FAX (212) 305-6891
- OUTPATIENT OFFICE LOCATION
- Irving Pavilion 9 907
- 161 Fort Washington Ave at W 165th St..
- PHYSICIAN SUMMARY
- Michael J. Hall, M.D., M.S. is an Assistant Professor of Medicine and Epidemiology at the New York Hospital-Columbia University Medical Center and the Columbia University Mailman School of Public Health. Dr. Hall specializes in clinical cancer genetics and gastrointestinal oncology. He performs risk assessment and genetic testing in high-risk individuals and families, and primarily treats cancers of the gastrointestinal system, including tumors originating from the esophagus, stomach, small bowel, liver, pancreas, appendix, colon and anus. He is also an active member of the multi-disciplinary Columbia University Pancreas Center www.columbiasurgery.org/pat/pancreas and is board certified in Medical Oncology and Hematology.
Dr. Hall received his undergraduate (1993 B.A., magna cum laude, Phi Beta Kappa) and medical education (1999 M.D., AOA) at Columbia University. After training in Internal Medicine at Harvard Medical School (1999-2002), Dr. Hall completed a three-year fellowship in Hematology/Oncology and a Masters of Health Services and Outcomes at the University of Chicago (2002-2005). He is an active clinician, educator, and clinical researcher through the Herbert Irving Comprehensive Cancer Center (HICCC) www.ccc.columbia.edu and the Mailman School of Public Health www.mailman.hs.columbia.edu, and is the recipient of research funding from the Chemotherapy Foundation www.chemotherapyfoundation.org, the American Cancer Society www.cancer.org, and the Columbia University/Long Island University U54 Program.
Dr. Hall is involved in clinical research in several areas, including cancer prevention in individuals at increased risk for cancer due to inherited genetic predisposition, impact and disparities in cancer outcomes related to clinical genetics and genetic technology, and costs and benefits associated with the incorporation of clinical genetics into cancer care. He is trained as an epidemiologist and primarily performs analyses using STATA®. He has active research collaborations with the Breast Cancer Family Registry www.cfr.epi.uci.edu , Long Island University, Myriad Genetic Laboratories, and the Integrated Cancer Prevention Program at the Sourasky Medical Center (Tel-Aviv, ISRAEL). Dr. Hall has written (gemcitabine + sorafinib in advanced pancreatic cancer) and is a co-investigator on several Phase II trials at the HICCC. He sits on the New York Presbyterian Hospital Pharmacogenomics Subcommittee and the HICCC Data Safety Monitoring Board. He has personally reviewed manuscripts for Cancer Epidemiology Biomarkers and Prevention and has co-authored reviews with several mentors (Journal of Clinical Oncology, ACP Journal Club). He is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the American Society of Preventive Oncology (ASPO).